Antibiotic Choice in Post Hip Replacement Infection
Empiric Therapy
Empiric antibiotics for prosthetic joint infection following hip replacement should include vancomycin 15 mg/kg IV every 12 hours PLUS an anti-gram-negative agent (cefepime 2 g IV every 12 hours or meropenem 1 g IV every 8 hours) until culture results are available. 1, 2
- This broad-spectrum approach covers the most common pathogens: methicillin-resistant Staphylococcus aureus (MRSA), methicillin-susceptible Staphylococcus aureus (MSSA), coagulase-negative staphylococci, and gram-negative organisms including Pseudomonas aeruginosa. 1, 2
- Staphylococci account for >50% of prosthetic joint infections, making anti-staphylococcal coverage essential. 3
- Obtain 3-6 intraoperative tissue samples before initiating antibiotics whenever possible to maximize diagnostic yield and guide definitive therapy. 4
Pathogen-Specific Definitive Therapy
Once culture results are available, narrow therapy based on the identified organism:
Staphylococci (Oxacillin-Susceptible)
- Preferred: Nafcillin 1.5-2 g IV every 4-6 hours OR cefazolin 1-2 g IV every 8 hours OR ceftriaxone 1-2 g IV every 24 hours 2, 4
- Alternatives: Vancomycin 15 mg/kg IV every 12 hours, daptomycin 6 mg/kg IV every 24 hours, or linezolid 600 mg PO/IV every 12 hours 2
- Add rifampin 300-450 mg PO twice daily (or 600 mg once daily) if debridement with implant retention or one-stage exchange is performed, but only after wounds are dry to prevent resistant organism superinfection. 2, 5
Staphylococci (Oxacillin-Resistant/MRSA)
- Preferred: Vancomycin 15 mg/kg IV every 12 hours 2
- Alternatives: Daptomycin 6 mg/kg IV every 24 hours or linezolid 600 mg PO/IV every 12 hours 2
- Add rifampin as above for retained implants 6, 2
- Target vancomycin trough of 15-20 mcg/mL for MRSA infections without rifampin or local vancomycin spacer; trough ≥10 mcg/mL may be adequate when rifampin or vancomycin-impregnated spacers are used. 1
Enterococcus (Penicillin-Susceptible)
- Preferred: Penicillin G 20-24 million units IV every 24 hours continuously or in 6 divided doses OR ampicillin 12 g IV every 24 hours continuously or in 6 divided doses 2
- Alternatives (penicillin allergy only): Vancomycin 15 mg/kg IV every 12 hours, daptomycin 6 mg/kg IV every 24 hours, or linezolid 600 mg PO/IV every 12 hours 2
- Aminoglycoside addition is optional 2
Pseudomonas aeruginosa
- Preferred: Cefepime 2 g IV every 12 hours OR meropenem 1 g IV every 8 hours 1, 2
- Alternatives: Ciprofloxacin 750 mg PO twice daily or 400 mg IV every 12 hours OR ceftazidime 2 g IV every 8 hours 1, 2
- Consider dual active drug therapy based on clinical severity 1, 2
Other Gram-Negative Bacilli
- Enterobacteriaceae: IV β-lactam based on susceptibilities OR ciprofloxacin 750 mg PO twice daily 2
- Enterobacter species: Cefepime 2 g IV every 12 hours OR ertapenem 1 g IV every 24 hours 2
Streptococci
- β-hemolytic streptococci: Penicillin G 20-24 million units IV every 24 hours OR ceftriaxone 2 g IV every 24 hours 2
- Vancomycin only for penicillin allergy 2
Propionibacterium acnes
- Preferred: Penicillin G 20 million units IV every 24 hours OR ceftriaxone 2 g IV every 24 hours 2
- Alternatives: Clindamycin 600-900 mg IV every 8 hours or 300-450 mg PO four times daily 2
Treatment Duration
The standard duration is 4-6 weeks of pathogen-specific IV or highly bioavailable oral antimicrobial therapy following surgical intervention. 1, 2
- For staphylococcal infections with implant retention: Extend to 3 months for hip infections and 6 months for knee infections when rifampin is used. 1
- IV therapy can be limited to 1-2 weeks until the patient is stable and culture results are known, then transition to oral therapy with highly bioavailable agents (e.g., fluoroquinolones, linezolid). 5
- After implant removal: 6 weeks is sufficient. 5
- With implant retention: 12 weeks total duration is recommended. 5
Critical Caveats and Pitfalls
Rifampin Use
- Never use rifampin monotherapy due to rapid resistance emergence. 5
- Do not start rifampin until after thorough debridement and when wounds are dry to avoid superinfection with resistant organisms. 5
- Fluoroquinolones are the preferred companion drug for rifampin in staphylococcal infections, but never use fluoroquinolone monotherapy against staphylococci due to high failure rates. 5
- Alternative rifampin companions include TMP-SMX, minocycline, or fusidic acid (less studied). 5
Monitoring and Safety
- Monitor for QTc prolongation when using fluoroquinolones and discuss tendinopathy risk. 1, 2
- Monitor for Clostridium difficile colitis with any antimicrobial. 1, 2
- Adjust dosing for renal and hepatic dysfunction. 1, 2, 4
- Follow published guidelines for outpatient IV antimicrobial monitoring. 1, 2, 4
Surgical Considerations
- The timing of infection presentation (early ≤3 months, delayed 3-24 months, late >24 months) influences both microbiology and surgical approach. 3
- Debridement and implant retention (DAIR) has a 57% success rate in early infections but fails more often with MRSA (73% failure rate). 7
- Successful treatment requires adequate surgical debridement combined with appropriate antimicrobial therapy, as biofilm formation makes these infections difficult to eradicate. 8, 9
Chronic Suppressive Therapy
- Indefinite chronic oral antimicrobial suppression may be considered after completing initial therapy for patients unsuitable for further surgery, based on in vitro susceptibilities. 1, 2
- For staphylococci: cephalexin, dicloxacillin, TMP-SMX, or minocycline/doxycycline 2
- Rifampin alone is not recommended for chronic suppression. 2